Drug re-purposing to improve outcomes in the management of prostate cancer – aims, outcome measures and design of current phase III trials
Abstract Prostate cancer remains a major cause of cancer morbidity and mortality and is rising in incidence across the world. Although a succession of randomised controlled trials have improved outcomes across all stages of disease, there remain significant clinical challenges and unmet needs. Repur...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2026-01-01
|
| Edice: | BMC Pharmacology and Toxicology |
| On-line přístup: | https://doi.org/10.1186/s40360-025-01077-w |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
